These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 29564747

  • 1. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD.
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [Abstract] [Full Text] [Related]

  • 2. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
    Fukuoka S, Kojima T, Koga Y, Yamauchi M, Komatsu M, Komatsuzaki R, Sasaki H, Yasunaga M, Matsumura Y, Doi T, Ohtsu A.
    Oncotarget; 2017 Feb 14; 8(7):11020-11029. PubMed ID: 28038457
    [Abstract] [Full Text] [Related]

  • 3. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
    Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Jørgensen TK, Hey A, Kragh M.
    Clin Cancer Res; 2011 Sep 15; 17(18):5962-72. PubMed ID: 21825041
    [Abstract] [Full Text] [Related]

  • 4. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
    Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.
    Mol Cancer Ther; 2015 Jul 15; 14(7):1614-24. PubMed ID: 25931519
    [Abstract] [Full Text] [Related]

  • 5. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
    Wei JW, Cui JQ, Zhou X, Fang C, Tan YL, Chen LY, Yang C, Liu M, Kang CS.
    Cancer Lett; 2016 Sep 28; 380(1):1-9. PubMed ID: 27317648
    [Abstract] [Full Text] [Related]

  • 6. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
    Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.
    Mol Cancer Ther; 2015 May 28; 14(5):1141-51. PubMed ID: 25731184
    [Abstract] [Full Text] [Related]

  • 7. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.
    Clin Cancer Res; 2016 Jul 01; 22(13):3260-7. PubMed ID: 26888827
    [Abstract] [Full Text] [Related]

  • 8. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
    Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL.
    Neoplasia; 2013 Oct 01; 15(10):1196-206. PubMed ID: 24204198
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
    Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR.
    J Pharmacokinet Pharmacodyn; 2020 Feb 01; 47(1):5-18. PubMed ID: 31679083
    [Abstract] [Full Text] [Related]

  • 10. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 01; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 11. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z, Jia X, Jiang T, Zhang J, Li X, Kang C, Ren H.
    Neuro Oncol; 2014 Sep 01; 16(9):1229-43. PubMed ID: 24861878
    [Abstract] [Full Text] [Related]

  • 12. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 13. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
    Nakazawa T, Murakami T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Park YS, Motoyama Y, Tsujimura T, Wakabayashi T, Nakase H.
    Anticancer Res; 2020 Jun 01; 40(6):3231-3237. PubMed ID: 32487617
    [Abstract] [Full Text] [Related]

  • 14. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, Kaur B, Caligiuri MA, Yu J.
    Sci Rep; 2015 Jul 09; 5():11483. PubMed ID: 26155832
    [Abstract] [Full Text] [Related]

  • 15. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
    Liu Z, Han L, Dong Y, Tan Y, Li Y, Zhao M, Xie H, Ju H, Wang H, Zhao Y, Zheng Q, Wang Q, Su J, Fang C, Fu S, Jiang T, Liu J, Li X, Kang C, Ren H.
    Oncotarget; 2016 Jan 26; 7(4):4680-94. PubMed ID: 26717039
    [Abstract] [Full Text] [Related]

  • 16. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
    Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M.
    Cancer Res; 2010 Jan 15; 70(2):588-97. PubMed ID: 20068188
    [Abstract] [Full Text] [Related]

  • 17. Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts.
    Goodwin CR, Rath P, Oyinlade O, Lopez H, Mughal S, Xia S, Li Y, Kaur H, Zhou X, Ahmed AK, Ho S, Olivi A, Lal B.
    Clin Neurol Neurosurg; 2018 Aug 15; 171():26-33. PubMed ID: 29803091
    [Abstract] [Full Text] [Related]

  • 18. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL.
    J Biol Chem; 2015 Jun 12; 290(24):14798-809. PubMed ID: 25837250
    [Abstract] [Full Text] [Related]

  • 19. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
    Liu X, Dong C, Shi J, Ma T, Jin Z, Jia B, Liu Z, Shen L, Wang F.
    Oncotarget; 2017 Jan 24; 8(4):6364-6375. PubMed ID: 28031526
    [Abstract] [Full Text] [Related]

  • 20. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L, Shen D, Liang D, Shi J, Song C, Jiang K, Menglin Ren, Du S, Cheng W, Ma J, Li S, Bi X, Barr MP, Fang Z, Xu Q, Li W, Piao H, Meng S.
    Cancer Lett; 2020 Nov 28; 493():156-166. PubMed ID: 32860853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.